OSE Immuno

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

03 апр 2025 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

26 мар 2025 12:20:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

11 мар 2025 12:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

06 мар 2025 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

24 фев 2025 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

20 фев 2025 11:05:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

29 янв 2025 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

28 янв 2025 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13 янв 2025 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

11 дек 2024 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

02 дек 2024 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

04 ноя 2024 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

17 окт 2024 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

26 сен 2024 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer

10 сен 2024 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis

24 июл 2024 01:55:00 Источник Nasdaq GlobeNewswire

Boehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371

03 июл 2024 11:00:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

01 июл 2024 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Commercial and Revenue Sharing Agreement in the Field of CAR T-cell Therapies

24 июн 2024 00:30:00 Источник Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Preclinical Data on mRNA Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders at the FOCIS Annual Meeting, San Francisco (June 18 – 21)

20 июн 2024 00:30:00 Источник Nasdaq GlobeNewswire